Zeldox (ziprazidone) capsules 40 mg. №28


Ziprasidone is indicated for the treatment of schizophrenia in adults. Ziprasidone is indicated for the treatment of manic or mixed episodes of moderate severity in patients with bipolar disorder (prevention of episodes of bipolar disorder has not been established).



Composition and form of release
It is produced in the form of hard capsules containing 40 mg of ziprasidone.
The active substance is ziprasidone.
Pharmacological properties
The active substance of the drug – ziprasidone, is similar to human serotonin and dopamine receptors. In the study of the effects of ziprasidone using positron emission tomography 12 hours after a single dose of 40 mg, a blockade of 2A serotonin receptors and D2 receptors was recorded. In addition, ziprasidone has been shown to act on serotonin receptors such as 5HT2C, 5HT1D and 5HT1A.
Zeldox is used to treat patients with schizophrenia. In addition, the drug is used in the treatment of patients with manic and mixed episodes occurring against the background of moderate bipolar disorder.
The drug is not used in the treatment of patients with ziprasidone intolerance, diagnosed with QT prolongation and congenital QT increase syndrome.
The drug is contraindicated in patients who have recently suffered an acute myocardial infarction or suffering from decompensated heart failure.
The capsules are not used in patients with arrhythmia treated with class IA and III drugs and in patients receiving drugs that potentially prolong the QT interval, such as arsenic trioxide, halofantrine, levometadil acetate, cisapride, pimozide and mefloquine.
Use during pregnancy and breastfeeding
Zeldox is contraindicated in pregnant and lactating women, as ziprasidone has a toxic effect on the fetus. The drug has no teratogenic effects.
Newborns whose mothers received antipsychotic drugs in the last trimester of pregnancy should be under medical supervision, as they are more likely to develop withdrawal or extrapyramidal disorders.
Method of application and dose
The capsules are taken orally with a meal. The dose, frequency of administration and duration of the course of therapy are selected by the specialist individually.
Adult patients in the treatment of bipolar disorder and schizophrenia are prescribed 40 mg twice a day. With good tolerability, the dose of ziprasidone can be increased to 80 mg if necessary. Dosage increase is possible only on the third day of treatment. It is not recommended to take more than 160 mg of ziprasidone in a knock due to the lack of information on the safety and effectiveness of the drug in high doses.
After the main course of treatment, it is possible to take the drug twice a day in a maintenance dosage of 20 mg.
There are very few reports of overdose with Zeldox, but it is known that patients receiving high doses of ziprasidone may develop extrapyramidal disorders, increased QT interval, increased drowsiness, anxiety, tremor, inhibition, convulsions and dystonic reactions.
In case of Zeldox poisoning, the patient is prescribed gastric lavage, monitoring of the cardiovascular system and symptomatic treatment.
Side effects
Rhinitis, loss of appetite, unexplained anxiety, chest tightness, depressive episodes, bradyphrenia, mania, hypomania, sleep disorders, extrapyramidal disorders, akathisia, dystonia, parkinsonism, headaches, tremor, generalized tonic-clonic convulsions paresthesias, hypertonia, restless legs and crooked neck syndrome, increased QT interval, orthostatic hypotension, hypertensive crisis, syncope, decreased visual acuity, dry eye mucosa, tinnitus, vertigo, dyspnea, dyspeptic disorders.
Conditions and terms of storage
Zeldox must be stored in its original packaging in a place protected from children. Shelf life of capsules – 4 years.